| review article | Q7318358 |
| scholarly article | Q13442814 |
| P2093 | author name string | Yusuke Nakamura | |
| Noura Choudhury | |||
| P2860 | cites work | CD28/B7 system of T cell costimulation | Q24313544 |
| Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade | Q24535835 | ||
| Improved Endpoints for Cancer Immunotherapy Trials | Q24603112 | ||
| Safety, activity, and immune correlates of anti-PD-1 antibody in cancer | Q24633070 | ||
| Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation | Q24675931 | ||
| Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma | Q24679736 | ||
| Immune Checkpoint Blockade in Cancer Therapy | Q26830509 | ||
| Nivolumab plus ipilimumab in advanced melanoma | Q27852310 | ||
| Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers | Q27853176 | ||
| CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma | Q35871798 | ||
| CTLA-4 is a second receptor for the B cell activation antigen B7 | Q36230356 | ||
| Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial | Q36726204 | ||
| PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors | Q37726682 | ||
| Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial | Q38364028 | ||
| T-cell receptor profiling in cancer | Q38592595 | ||
| B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma | Q40626031 | ||
| The immune checkpoint inhibitors: where are we now? | Q56896561 | ||
| Immunotherapy: The development of immunotherapy in urothelial bladder cancer | Q86945412 | ||
| Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma | Q27860650 | ||
| The blockade of immune checkpoints in cancer immunotherapy | Q27860852 | ||
| Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer | Q27860857 | ||
| Improved Survival with Ipilimumab in Patients with Metastatic Melanoma | Q27861062 | ||
| The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma | Q28088496 | ||
| Ipilimumab plus dacarbazine for previously untreated metastatic melanoma | Q28131634 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria | Q28265610 | ||
| Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 | Q28284177 | ||
| Hepatotoxicity with combination of vemurafenib and ipilimumab | Q28288255 | ||
| Restoring function in exhausted CD8 T cells during chronic viral infection | Q28289222 | ||
| Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma | Q29615443 | ||
| Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer | Q29615679 | ||
| Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients | Q29617771 | ||
| MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer | Q29617772 | ||
| Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy | Q29617774 | ||
| Pembrolizumab versus Ipilimumab in Advanced Melanoma | Q29618134 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab | Q29620596 | ||
| Nivolumab and ipilimumab versus ipilimumab in untreated melanoma | Q29620657 | ||
| Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial | Q29620814 | ||
| Pembrolizumab for the treatment of non-small-cell lung cancer | Q29620851 | ||
| PD-1 blockade induces responses by inhibiting adaptive immune resistance | Q29620856 | ||
| PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma | Q29620878 | ||
| Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer | Q29620902 | ||
| Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma | Q30890582 | ||
| Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. | Q33421351 | ||
| CTLA4 blockade broadens the peripheral T-cell receptor repertoire | Q33560753 | ||
| The future of cancer therapy: selecting patients likely to respond to PD1/L1 blockade | Q34288025 | ||
| Neoantigens in cancer immunotherapy. | Q34470074 | ||
| NY-ESO-1-specific TCR-engineered T cells mediate sustained antigen-specific antitumor effects in myeloma. | Q34485950 | ||
| Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial | Q34670965 | ||
| Whole-exome sequencing of muscle-invasive bladder cancer identifies recurrent mutations of UNC5C and prognostic importance of DNA repair gene mutations on survival | Q34717001 | ||
| Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens | Q34788858 | ||
| Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients | Q34959906 | ||
| Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer | Q35463514 | ||
| Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial | Q35567212 | ||
| A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma. | Q35617517 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| neoplasm | Q1216998 | ||
| immunotherapy | Q1427096 | ||
| antineoplastic | Q2853144 | ||
| patient selection | Q17092352 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 107-15 | |
| P577 | publication date | 2016-02-01 | |
| P1433 | published in | Cancer Science | Q326125 |
| P1476 | title | Importance of immunopharmacogenomics in cancer treatment: Patient selection and monitoring for immune checkpoint antibodies | |
| P478 | volume | 107 |
| Q53069347 | A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. |
| Q98736020 | Current Status and Future Perspectives of Immunotherapy in Middle-Income Countries: A Single-Center Early Experience |
| Q34046505 | Driving CAR T-cells forward |
| Q59351730 | EBV-associated gastric cancer evades T-cell immunity by PD-1/PD-L1 interactions |
| Q37295612 | Genetic polymorphisms of immune checkpoint proteins PD-1 and TIM-3 are associated with survival of patients with hepatitis B virus-related hepatocellular carcinoma |
| Q37399410 | Hepatitis C virus drives the pathogenesis of hepatocellular carcinoma: from immune evasion to carcinogenesis. |
| Q33686036 | Japanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cells |
| Q49968394 | PD-L1 is a promising blood marker for predicting tumor progression and prognosis in patients with gastric cancer |
| Q50035774 | Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors |
| Q37545590 | Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. |
Search more.